CJC-1295
Explored for stimulating growth hormone release, which may affect body composition and skin health. NOT FDA-approved with significant data gaps.
This peptide is not FDA-approved for any indication. Human use outside of clinical trials is not recommended.
The basics
- Generic Name
- CJC-1295 (growth hormone-releasing hormone analog)
- Brand Names
- None (not an approved product)
- Regulatory Status
- Early Research
- Therapeutic Areas
- Growth Hormone, Endocrine
Important: This peptide is not yet FDA-approved
CJC-1295 has not been approved by the FDA for any use in humans. That means it hasn't gone through the rigorous testing process that confirms a drug is safe and effective. Products sold online have not been evaluated by any regulatory body.
What it does
CJC-1295 (CJC-1295 (growth hormone-releasing hormone analog)) is a synthetic peptide that researchers are studying, but it's not yet FDA-approved for any human use. Synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates growth hormone secretion from the pituitary. DAC (Drug Affinity Complex) variants have extended half-life.
The research is still early. Most studies so far are in animals or lab settings, so we don't know for sure how well this translates to real-world results in people.
How it's taken
Subcutaneous injection (often combined with Ipamorelin)
How people access it
Category 1 compounding-eligible since February 2026. Requires a doctor's prescription sent to a compounding pharmacy. Often prescribed as a combination with Ipamorelin. Typical cost: $200-400/month for the combination.
Regulatory Status
Not FDA-approved. FDA compounding advisory committee materials highlight significant characterization and data gaps.
Any use in humans outside of an FDA-authorized clinical trial would require an Investigational New Drug (IND) application. Products marketed as “for research use only” are not legally intended for human administration.
What the Evidence Shows
The evidence base for CJC-1295 consists primarily of preclinical studies (animal models and in vitro experiments). There are no completed, large-scale, peer-reviewed clinical trials establishing safety or efficacy in humans. The gap between promising animal data and proven human benefit is substantial — many compounds that show effects in animal studies fail to demonstrate safety or efficacy in human trials.
Marketing claims made by online sellers and “peptide clinics” frequently overstate the evidence and omit critical information about risks and unknowns.
Other options to consider
Depending on what you're hoping to achieve, there may be FDA-approved treatments that have been rigorously tested and proven to work. Discuss evidence-based options with your own healthcare provider to find what fits your specific goals.
Browse our full peptide directory to see FDA-approved options that might work for you.
Common Questions
No. CJC-1295 is not FDA-approved for any indication. While it has appeared in some clinical trial registries, no completed trials have led to an approved NDA or BLA. It cannot be legally prescribed as a drug in the United States.
CJC-1295 DAC refers to a version of CJC-1295 modified with a Drug Affinity Complex, which extends its half-life by binding to albumin in the bloodstream. While this modification was explored in early clinical research, neither CJC-1295 nor CJC-1295 DAC has received FDA approval. Products sold under these names are not regulated pharmaceutical products.
CJC-1295 has appeared in clinical trial registries, primarily in early-phase studies examining growth hormone secretion. However, the FDA compounding advisory committee materials highlight significant characterization and data gaps. No trials have progressed to the point of supporting a regulatory approval.
Curious about what IS approved?
Check out FDA-approved peptides that address similar goals — with established safety profiles and real clinical evidence.
See Approved Options